Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050.
Xingxiang Pu, Juan Li, Bo Zhang, Jinyao Zhang, Tony S K Mok, Kazuhiko Nakagawa, Rafael Rosell, Ying Cheng, Xiangdong Zhou, Maria Rita Miglorino, Seiji Niho, Ki Hyeong Lee, Jesus Corral, Adam Pluzanski, Junling Li, Rolf Linke, Fang Pan, Yiyun Tang, Weiwei Tan, Lin Wu
Future Oncol 20(37) 2971-2982
摘要
摘要
Aim: We investigated association between skin adverse events (AEs) and efficacy with dacomitinib in patients with EGFR-positive non-small-cell lung cancer (NSCLC).Methods: Post hoc analyses from ARCHER 1050 evaluated efficacy in patients who did and did not experience grade ≥2 skin AEs with dacomitinib. Landmark analyses were performed at 3 and 6 months.Results: In patients who had skin AEs (72.2%) vs. those who did not (27.7%), median progression-free survival was 16.0 vs. 9.2 months, median overall survival (OS) was 37.7 vs. 21.6 months, and objective response rate was 80.2 vs. 61.5%; OS was improved at 3 and 6 months landmark analyses.Conclusion: Presence of grade ≥2 skin AEs was associated with numerically improved efficacy and represents a valuable biomarker of treatment outcome with dacomitinib in patients with advanced NSCLC.Clinical Trial Registration: NCT01774721 (ClinicalTrials.gov).
KM 提取结果
0 个 Figure · 0 个 KM 面板